Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst

benzinga.com/analyst-stock-ratings/downgrades/25/06/46003836/eli-lillys-1-3-billion-verve-deal-signals-confidence-in-gene-editing-space-analy

On Tuesday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Verve Therapeutics, Inc. (NASDAQ:VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.
Lilly offered to purchase Verve for $10.50 per share in cash, an aggregate of approximately…

This story appeared on benzinga.com, 2025-06-18 17:59:21.
The Entire Business World on a Single Page. Free to Use →